Back to articles
Comparative guide · 6 min read

NMN vs NR — the NAD+ precursors compared honestly

Updated 2026-05-11 · Reviewed by SupplementScore editors · No sponsorships

Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are both NAD+ precursors — small molecules that the body converts into NAD+, the central redox coenzyme that declines with age and that fuels sirtuin enzymes, PARP DNA repair enzymes, and CD38. Both raise blood NAD+ in human trials. Both are marketed aggressively for longevity. The actual evidence base — clinical endpoints rather than NAD+ levels — is small, inconsistent, and far short of what the marketing implies. The two compounds are more similar than different in human outcomes to date.

Quick verdict

GoalBetter choiceWhy
Demonstrated lifespan or healthspan extension in humans Neither No human trial of either compound has tested lifespan; clinical endpoint improvements in healthy aging are small or absent.
Reliably raises whole-blood NAD+ Both Multiple trials of each show dose-dependent NAD+ elevation in blood within days to weeks.
Regulatory status (US) NR (clearer) NR (Niagen) holds NDI and GRAS status as a dietary ingredient; NMN's status is contested — FDA has suggested NMN is being investigated as a drug, complicating supplement marketing.
Cost per day at typical dose NR (slightly cheaper) Brand-name NR (Niagen) at 300 mg/day: $1.50–2.50/day. NMN 250–500 mg/day: $1.00–3.00/day. Generic NMN can be cheaper but quality varies.
Patent / brand quality verification NR (Niagen has the trials) Most peer-reviewed NR trials used Niagen specifically; generic NR varies. NMN quality varies widely across brands; third-party purity testing is essential.
Cardiometabolic improvement Both show small, inconsistent signals Small trials of NR show modest BP reductions in some populations; NMN trials show small signals on insulin sensitivity. Neither has produced a robust endpoint shift.

How they compare on the things that matter

The mechanism story — and where it breaks down

The premise: NAD+ declines with age across tissues; raising NAD+ should restore mitochondrial function, fuel sirtuin enzymes, and reverse some age-related decline. The animal data (mostly in rodents) supports parts of this story; the human translation is much weaker. Raising blood NAD+ does not guarantee raising NAD+ in the tissues that matter (skeletal muscle, brain, liver); some trials have measured intracellular NAD+ shifts and others haven't. The downstream metabolic and physiological consequences in healthy aging adults have been modest at best.

Pharmacokinetics — minor differences, similar endpoint

Oral NR is rapidly absorbed and elevates whole-blood NAD+ within hours; chronic dosing produces sustained elevation. Oral NMN was originally thought to require conversion to NR before crossing membranes, but more recent work has identified a putative NMN-specific transporter (Slc12a8) and direct NMN uptake into some tissues — although the human relevance of this is contested. Practically, both forms raise blood NAD+ in human trials to a similar degree at comparable doses (200–600 mg/day).

The endpoint problem

Most NR and NMN human trials have either reported NAD+ levels as the primary outcome (a biomarker, not a clinical endpoint) or have reported small mixed signals on secondary endpoints like blood pressure, insulin sensitivity, walking distance in older adults, or muscle strength. None of the published trials are large enough or long enough to detect mortality or major cardiovascular event differences. The Martens 2018 NR trial in middle-aged adults showed reduced systolic BP in a subgroup with elevated baseline BP; the Yoshino 2021 NMN trial in postmenopausal women showed improved muscle insulin sensitivity; the Igarashi 2022 NMN trial in older Japanese adults showed small improvements in gait. None of these is anywhere near "longevity supplement" territory in effect size.

Practical rule. For users determined to take an NAD+ precursor: NR (brand-name Niagen specifically, where the human trial evidence lives) at 300 mg/day is the more evidence-anchored choice. For users who prefer NMN for the longevity-marketing reasons: 250–500 mg/day from a brand with third-party purity testing. For users who don't yet supplement either: there is no clinical-endpoint evidence strong enough to make this a priority. Spend the money on weight, sleep, exercise, blood pressure, and not smoking before adding NAD+ precursors.

Dose and form

For NR: trial-cited doses range from 100 mg/day to 1,000 mg/day, with 250–500 mg/day being typical. Niagen is the patented branded form used in most peer-reviewed trials. Once daily or split twice daily; with or without food.

For NMN: trial-cited doses range from 250 mg/day to 1,000 mg/day. Most modern human trials use 250–500 mg/day. Stability of NMN at room temperature has been a quality concern — some products degrade meaningfully. Brand-name beta-NMN with third-party COA (certificate of analysis) for purity and isomer composition is preferable.

Safety

Both are generally well-tolerated in trials to date. Common adverse effects across both: mild GI upset, flushing (occasionally), headache. Long-term safety data is limited — most trials are 4–12 weeks; few extend beyond 6 months. Both flood the salvage NAD+ pathway with substrate; theoretical concerns include effects on methylation (excess nicotinamide can deplete methyl groups), CD38 activation, and modulation of tumour biology in active malignancy. These concerns have not produced safety signals in published trials but reflect why long-term use in healthy adults remains an experiment.

Pregnancy and lactation: insufficient data; avoid. Active malignancy: discuss with oncology team; some preclinical signals raise concern about NAD+ availability for tumour cells, though human translation is unclear.

Regulatory wrinkle

In the US, NR (specifically the Niagen form) holds NDI (new dietary ingredient) and GRAS (generally recognised as safe) status. NMN's regulatory status is contested: in 2022 the FDA indicated that NMN is being investigated as a drug, which under the dietary supplement provisions of the Federal Food, Drug, and Cosmetic Act would preclude its sale as a supplement. The regulatory situation has fluctuated; manufacturers have continued to market NMN. The practical implications: NMN's supply chain and quality control is less standardised than NR's.

Who should skip each

Pregnancy and lactation — both, insufficient data. Active malignancy — both, discuss with oncology. Users with active gout: theoretical concern about excess nicotinamide and uric acid metabolism; modest. Users on chronic medications: no major specific interactions documented but data is thin.

What we'd actually buy

For most healthy adults considering experimental longevity adjuncts: there is no high-value purchase here. Money is better spent on exercise (resistance + zone 2 cardio), sleep quality, blood pressure control, and dietary protein adequacy — all with much larger human evidence bases for healthspan.

For users determined to take an NAD+ precursor: brand-name NR (Niagen) at 300 mg/day, once daily, on a 6-month trial. Re-evaluate; the trial endpoint to track is whichever specific outcome you cared about (e.g., subjective energy, BP if elevated, exercise tolerance) — not NAD+ levels themselves.

For users committed to NMN: a brand with third-party COA for purity, β-isomer content, and absence of contaminants. 250–500 mg/day. Same caveat: the clinical-endpoint evidence is weak.

Sources

Read more: